We are happy to announce a new collaboration with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, through its Janssen Human Microbiome Institute (JHMI), focused on DayTwo’s products and research conducted at the Weizmann Institute of Science, in Rehovot, Israel. The agreement was facilitated by Johnson & Johnson Innovation.
“DayTwo’s advanced prediction engine algorithm, the Weizmann Institute of Science’s robust research capabilities … provide unique opportunities to learn more about the role that the microbiome plays in disease and health” Anuk Das, head of scientific innovation, Janssen Human Microbiome Institute
DayTwo and the Weizmann Institute scientists will work together with Janssen to evaluate DayTwo’s platform for the effective interception of gestational diabetes mellitus (GDM), type 2 diabetes mellitus (T2DM) and metabolic syndrome-associated disorders. This newest collaboration with Janssen is the latest in a series of high profile collaborations with leading health related organizations in the US, including the Mayo Clinic.
“We believe J&J’s experience in developing diagnostic and therapeutic products will help us introduce new and groundbreaking innovations that promote individual health” Lihi Segal, CEO, Daytwo
“Working with the Janssen Human Microbiome Institute and its internal and external network is an exciting and beneficial opportunity for us,” said Lihi Segal, Co-founder and CEO of Daytwo. “This collaboration will create critical new insights to address metabolic disorders through microbiome-based diagnostics and therapeutics and we believe Janssen’s experience in developing diagnostic and therapeutic products will help us introduce new and groundbreaking innovations that promote individual health.”